|Bid||1,863.00 x 16300|
|Ask||1,864.00 x 34600|
|Day's Range||1,862.00 - 1,888.00|
|52 Week Range||814.20 - 2,033.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2017 - Mar 20, 2017|
|Forward Dividend & Yield||0.19 (0.97%)|
|1y Target Est||20.35|
Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC , today announced the appointment of Kristy Ronco as Executive Vice President, Sales and Marketing for its Generics Division.
I am going to run you through how I calculated the intrinsic value of Hikma Pharmaceuticals PLC (LON:HIK) by projecting its future cash flows and then discounting them to today’sRead More...
By Kit Rees and Helen Reid LONDON (Reuters) - Britain's top share index sank on Wednesday as emerging markets stress and a sharp selloff in commodities drove down stocks across Europe, with investors running ...
The Jordanian drugmaker said it sold more injectable opioids in the United States due to a supply shortage, and had a better-than-forecast performance in generics for the first half of the year as its prices proved more resilient than expected. The higher forecast in generics comes as global generic drugmakers with operations in the U.S. cut profit forecasts because of pricing pressure. Novartis said last month that 2018 sales at its generics unit, Sandoz, would fall in the low single-digit percentages, after previously holding out hopes for them to remain steady.
European Corporate Roundup for Wednesday Admiral Group 1H Interim Profit Rose on Motor-Unit Growth Admiral Group PLC said Wednesday that its first-half profit rose on growth in its core U.K. motor-insurance business, despite poor weather hurting its household unit.
I am going to take a deep dive into Hikma Pharmaceuticals PLC’s (LON:HIK) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comes toRead More...
LAS VEGAS (AP) — A maker of the powerful synthetic opioid fentanyl joined a bid Monday to block the use of its product in what would be the first execution in Nevada in more than 12 years using a three-drug combination never before tried in any state.
London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.
Hikma Pharmaceuticals PLC (the Hikma Group) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), the multinational generic pharmaceutical company, announced today that its US business has begun releasing significant quantities of hydromorphone to US hospital customers to help ease a current shortage of injectable opioids used to treat patients. In response to this shortage, Hikma released more than five million hydromorphone 2ml vials to US hospitals during June, and expects to release another three million vials during July. The current US hospital shortage of injectable opioids used for patient pain management occurred when a significant supplier to the US market temporarily ceased manufacturing.
The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million (407 million pounds) and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals (TEVA.TA), was named Hikma's chief executive officer in February. The company suffered a setback in March for its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair, after the U.S. Food and Drug Administration asked Hikma to conduct a further clinical study evaluating the drug, dashing hopes to get it to the market this year.
Hikma Pharmaceuticals Plc on Friday reaffirmed its revenue guidance for the full year, noting its generics business was performing better due to a favourable product mix, despite continued pricing pressure in the United States. The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals, was named Hikma's chief executive officer in February.
A large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over time. Over the past 10 years, Hikma Pharmaceuticals PLC (LSE:HIK) hasRead More...
I am going to run you through how I calculated the intrinsic value of Hikma Pharmaceuticals PLC (LSE:HIK) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
MADISON, Wis., April 2, 2018 /PRNewswire/ -- Today Propeller Health and peer-reviewed healthcare journal, Health Affairs, published results from a cross-sector partnership in Louisville, KY, that successfully reduced the burden of asthma. AIR Louisville, one of the largest studies of asthma conducted in a real-world setting, was a collaboration among 25 public, private and philanthropic organizations to use digital health technology to improve asthma. Partners and paper co-authors included representatives from city government such as the Mayor and agencies including Civic Innovation and Public Health, local business leaders and clinical providers, and nonprofit partner, the Institute for Healthy Air Water and Soil.
Hikma Pharmaceuticals PLC (LSE:HIK), a pharmaceuticals company based in United Kingdom, led the LSE gainers with a relatively large price hike in the past couple of weeks. As a mid-capRead More...